Resmed to Report Fourth Quarter Fiscal 2025 Earnings on July 31, 2025

GlobeNewswire Inc.

July 01, 2025 8:05PM GMT

SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2025 on Thursday, July 31, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.

Earnings webcast details:

 

Location:

https://investor.resmed.com

 

Date:

Thursday, July 31, 2025

 

Time:

1:30 p.m. PDT / 4:30 p.m. EDT

 

International:

London, Thursday, July 31, 2025, 9:30 p.m. BST

Sydney, Friday, August 1, 2025, 6:30 a.m. AEST

 

 

 

 

Please note, Resmed does not use outside phone lines to access the earnings call, the call is accessible via the above webcast link only.

A replay of the earnings webcast will be accessible on Resmed’s investor relations website and available approximately two hours after the webcast. In addition, a phone replay will be available approximately three hours after the webcast and will be accessible from July 31, 2025, until August 14, 2025, at:

 

U.S.: +1 877.660.6853

 

International: +1 201.612.7415

 

Conference ID: 13754703

 

 

 

About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.

For investors

For media

+1 858.836.5000

+1 619.510.1281

investorrelations@Resmed.com

news@Resmed.com